We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

49 hedge funds and large institutions have $13.7M invested in Karyopharm Therapeutics in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 30 reducing their positions, and 42 closing their positions.

New
Increased
Maintained
Reduced
Closed

512% more call options, than puts

Call options by funds: $581K | Put options by funds: $95K

39.82% more ownership

Funds ownership: 3.22% → 43.04% (+40%)

44% less funds holding

Funds holding: 87 → 49 (-38)

67% less capital invested

Capital invested by funds: $41.2M → $13.7M (-$27.5M)

73% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 30

90% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 42

Holders
49
Holders Change
-38
Holders Change %
-43.68%
% of All Funds
0.66%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
8
Reduced
30
Closed
42
Calls
$581K
Puts
$95K
Net Calls
+$486K
Net Calls Change
+$337K

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$1.3M
2
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$1.19M
3
Bank of America
Bank of America
North Carolina
+$1.04M
4
EP
Eversept Partners
New York
+$1.01M
5
UBS Group
UBS Group
Switzerland
+$716K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$1.91M
2
GCP
GSA Capital Partners
United Kingdom
-$1.08M
3
Deutsche Bank
Deutsche Bank
Germany
-$863K
4
KCM
Kennedy Capital Management
Missouri
-$808K
5
UOC
UBS O'Connor
Illinois
-$643K
Name Holding Trade Value Shares
Change 		Change in
Stake
KIG
76
Kennedy Investment Group
New Jersey
– -$23.7K -2,333 Closed
RS
77
R Squared
Hong Kong
– -$20.1K -1,978 Closed
EGM
78
Engineers Gate Manager
New York
– -$19.4K -1,913 Closed
Commonwealth Equity Services
79
Commonwealth Equity Services
Massachusetts
– -$15K -1,486 Closed
Squarepoint
80
Squarepoint
New York
– -$14.1K -1,386 Closed
Corient Private Wealth
81
Corient Private Wealth
Florida
– -$13.9K -1,367 Closed
ACM
82
ADAR1 Capital Management
Texas
– -$13.5K -1,333 Closed
EM
83
ELCO Management
New York
– -$10.9K -1,078 Closed
WAG
84
Winthrop Advisory Group
Massachusetts
– -$10.1K -1,000 Closed
CG
85
Caprock Group
Idaho
– -$7.84K -773 Closed
SCA
86
Snowden Capital Advisors
New York
– -$7.44K -733 Closed
Walleye Capital
87
Walleye Capital
New York
– -$7.07K -697 Closed
Wolverine Trading
88
Wolverine Trading
Illinois
– -$7.19K -685 Closed
BBA
89
BLB&B Advisors
Pennsylvania
– -$6.86K -677 Closed
Janney Montgomery Scott
90
Janney Montgomery Scott
Pennsylvania
– -$7K -667 Closed
TRCT
91
Tower Research Capital (TRC)
New York
– -$5.2K -513 Closed
Wells Fargo
92
Wells Fargo
California
– -$450 -44 Closed
1 2 3
4

KPTI Hedge Fund Activity: Q1 2025 in Review

49 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2025, worth a combined $13.7M — down 67% from $41.2M a quarter earlier.

Sellers outnumbered buyers: 42 funds closed out of KPTI and 4 opened new positions — a net loss of 38 holders — while 30 trimmed existing stakes and 8 added.

The largest buyer was JP Morgan Chase, adding an estimated $1.3M. The largest seller was Morgan Stanley, cutting an estimated $1.91M.

  • 49 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2025, down from 87 in Q4 2024.
  • Funds reported $13.7M of Karyopharm Therapeutics stock for Q1 2025, down 67% quarter-over-quarter.
  • 4 funds opened new Karyopharm Therapeutics positions in Q1 2025 and 42 closed out, a net change of -38 holders.
  • The largest Karyopharm Therapeutics buyer in Q1 2025 was JP Morgan Chase, an estimated $1.3M added.
  • The largest Karyopharm Therapeutics seller in Q1 2025 was Morgan Stanley, an estimated $1.91M sold.

Based on aggregated 13F filings for Q1 2025.